Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS (IST:ECILC) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's Enterprise Value for the quarter that ended in Mar. 2026 was ₺71,664 Mil.
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺806 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS EV-to-EBIT Related Terms
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS EV-to-EBIT Chart
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS EV-to-EBIT vs Drug Manufacturers Industry
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's current Enterprise Value is ₺50,216 Mil.
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺806 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS (IST:ECILC) has a EV-to-EBIT of 62.28 as of Jul. 18, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS and its competitors. This is 703% above median its historical median of 7.76. Over the past decade, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's EV-to-EBIT has ranged from 2.50 to 93.64. According to the industry distribution chart, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS ranks #612 out of 689 companies in the Drug Manufacturers industry, placing it in the top 88.8%.
Is EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's EV-to-EBIT too high?
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's current EV-to-EBIT of 62.28 is 703% above median its 10-year median of 7.76. Over the past 10 years, this metric has ranged from a low of 2.50 to a high of 93.64. The Drug Manufacturers industry median EV-to-EBIT is 15.73. EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's value of 62.28 is 295.9% above this industry median. Based on the distribution chart, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS ranks #612 out of 689 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS has a GF Score™ of 63/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS ranks #612 out of 689 companies for EV-to-EBIT. This places EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS in the lower half of its industry. The industry median EV-to-EBIT is 15.73. EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's value of 62.28 is 295.9% above this benchmark. Historically, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's own EV-to-EBIT has ranged from 2.50 to 93.64 over the past decade. While the company's 10-year median is 7.76 vs. the industry median of 15.73, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.73, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's current EV-to-EBIT of 62.28 is 295.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's current EV-to-EBIT is 62.28, which is 703% above median its own 10-year median of 7.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS stock overvalued right now?
Based on GuruFocus' analysis, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS (IST:ECILC) is currently considered Modestly Overvalued. The stock's GF Value™ is ₺61.07, compared to a current price of ₺73.50 — trading 20.4% above its estimated fair value. The current EV-to-EBIT is 62.28, which is 703% above median its 10-year median of 7.76 and 295.9% above the Drug Manufacturers industry median of 15.73. EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS (IST:ECILC), the current EV-to-EBIT is 62.28 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS (IST:ECILC) Overvalued in 2026?
Based on GuruFocus' analysis, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS stock appears to be overvalued.
The current stock price of ₺73.50 is trading 20.4% above its estimated GF Value™ of ₺61.07.
GuruFocus considers EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS to be Modestly Overvalued.
Key valuation signals for IST:ECILC:
EV-to-EBIT: 62.28 (703% above median its 10-year median of 7.76)
GF Value™: ₺61.07 vs. price of ₺73.50 (20.4% above fair value)
Industry Position: 295.9% above the Drug Manufacturers median (#612 of 689)
No single metric tells the full story. See the IST:ECILC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS Business Description
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS is a Turkey-based company that operates in the drug business. It is mainly involved in the manufacturing of pharmaceuticals, veterinary drugs, and personal care products. Further, the group is also engaged in real estate development and leasing commercial property activities. Geographically, all the activities are carried out through the region of Turkey.
63GF Score
Get the complete analysis for IST:ECILC
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:ECILC has been successfully added to your 
